← Research library

Thymopentin and infections in a peritoneal dialysis cohort

Observational study · 2025

What was studied
100 peritoneal dialysis patients from a single center, 50 treated with thymopentin and 50 controls.
Main finding
Infection episodes · 36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034).

Reported findings and study design

Reported findings

Retrospective cohort with 48 weeks of follow-up. The thymopentin protocol was 10 mg subcutaneously on each of the first five days, then three times weekly for 23 weeks.

Population or model 100 peritoneal dialysis patients from a single center, 50 treated with thymopentin and 50 controls.

Dose, route and schedule

Retrospective cohort with 48 weeks of follow-up. The thymopentin protocol was 10 mg subcutaneously on each of the first five days, then three times weekly for 23 weeks.

Protocol source ↗ · Original full text, including the infection and safety tables.

Results · Original full text, including the infection and safety tables.
MeasureResultComparison, timing and statistics
Infection episodes36 versus 49, or 0.73 versus 1.00 episodes per person-year. Adjusted hazard ratio for first infection 0.54 (95% CI 0.30–0.95, p=0.034).
Peritonitis episodes1 versus 8 (p=0.031).
Severe infection and mortality5 versus 10 severe infections (p=0.161). One patient died in each group.
IL-6 at week 12The full results show a smaller median increase (0.20 versus 1.10 pg/mL, p=0.036). There was no significant difference at weeks 24 or 48.
Cell counts and adverse-event reportingNo significant differences in CD4 counts or the CD4:CD8 ratio. The authors reported 12 versus 24 adverse events.
Reported events during 48 weeks
Reported events during 48 weeks
MeasureThymopentin (n=50)Control (n=50)
Infection episodes3649
Infection episodes per person-year0.731.00
Peritonitis episodes18
Severe infection510
Deaths11
Reported adverse events1224

Treatment was selected in routine care. Differences in patients or care may have influenced the association. The study was small for severe infection and mortality. The article reports partial funding from the thymopentin manufacturer.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • Treatment was selected in routine care. Differences in patients or care may have influenced the association. The study was small for severe infection and mortality. The article reports partial funding from the thymopentin manufacturer.

Source details

Original full text, including the infection and safety tables.

Sources checked

Added to the library

Citation

Uncontrolled human reportFull text available

X. Chen, Y. Ruan, J. Xie, X. Huang, C. Zhang, Y. Cui, T. Xu, H. Ren. Thymopentin and infections in a peritoneal dialysis cohort BMC Nephrology 26, article 538

Study source ↗ · DOI 10.1186/s12882-025-04465-w · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards